HER-2 Positive Breast Cancer Completed Phase 2 Trials for Trastuzumab (DB00072)

IndicationStatusPhase
DBCOND0042425 (HER-2 Positive Breast Cancer)Completed2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT01305941A Study Of Everolimus, Trastuzumab And Vinorelbine In HER2-Positive Breast Cancer Brain MetastasesTreatment